Identification of candidate prostate cancer biomarkers in prostate needle biopsy specimens using proteomic analysis

Abstract

Although serum prostate specific antigen (PSA) is a well-established diagnostic tool for prostate cancer (PCa) detection, the definitive diagnosis of PCa is based on the information contained in prostate needle biopsy (PNBX) specimens. To define the proteomic features of PNBX specimens to identify candidate biomarkers for PCa, PNBX specimens from patients with PCa or benign prostatic hyperplasia (BPH) were subjected to comparative proteomic analysis. 2-DE revealed that 52 protein spots exhibited statistically significantly changes among PCa and BPH groups. Interesting spots were identified by MALDI-TOF-MS/MS. The 2 most notable groups of proteins identified included latent androgen receptor coregulators and FKBP4] and enzymes involved in mitochondrial fatty acid b-oxidation (DCI and ECHS1). An imbalance in the expression of peroxiredoxin subtypes was noted in PCa specimens. Furthermore, different post-translationally modified isoforms of HSP27 and HSP70.1 were identified. Importantly, changes in FLNA(7-15), FKBP4, and PRDX4 expression were confirmed by immunoblot analyses. Our results suggest that a proteomics-based approach is useful for developing a more complete picture of the protein profile of PNBX specimen. The proteins identified by this approach may be useful molecular targets for PCa diagnostics and therapeutics. ' 2007 Wiley-Liss, Inc.

Attenuation of enoyl coenzyme A hydratase short chain 1 expression in gastric cancer cells inhibits cell proliferation and migration in vitro

“…Therefore, increased ECHS1 expression may lead to overproliferation of cancer cells. Consistent with previous reports regarding colorectal, prostate, and liver cancers [15,16,19,27,28], our results showed that ECHS1 is highly expressed in gastric cancer cells, correlated with the degree of cell differentiation. Attenuation of ECHS1 expression by shRNA inhibited BGC-823 cell proliferation.…”

“…In recent years, ECHS1 has been implicated in many cancers, including breast, prostate, colon and liver cancer [14][15][16][17][18][19]. ECHS1 levels were found to be elevated in needle biopsy samples from prostate cancer patients [16] and in liver cancer cells [17,18]. Reducing ECHS1 expression in hepatocellular carcinoma cells with shRNA inhibits PKB activation and tumor growth in xenograft mice [19].…”

Downregulation of FKBP14 by RNA interference inhibits the proliferation, adhesion and invasion of gastric cancer cells

“…FKBP14 belongs to the FKBP family, which perform important biological functions in the cell. Several members of the FKBP family are established to contribute to carcinogenesis, including FKBP12 (5,6), FKBP65 (7) and FKBP52 (8)(9)(10), while other FKBPs are downregulated in human cancer, including FKBP38 (11). However, the functions of FKBP14 in human cancer remain to be elucidated.…”

“…FKBP65 expression was increased in early benign lesions compared with normal mucosa (7). FKBP52 has been demonstrated to be overexpressed in breast (8), prostate (9) and hepatocellular carcinoma tissues (10). FKBP38 has also been found to be selectively downregulated in aggressive types of schwannoma tumor cell lines (11).…”

Serum biomarker screening for the diagnosis of early gastric cancer using SELDI-TOF-MS

“…Over the years, SELDI-TOF-MS has been successfully applied in many types of tumors. A number of biomarkers in this process have been identified and further characterized, associated with cancers such as breast (16)(17)(18), liver (19)(20)(21), lung (22,23), prostate (24) and ovarian cancers (25). These studies suggest that SELDI-TOF-MS ProteinChip technology can distinguish cancer patients from normal subjects with relatively high sensitivity and specificity.…”